RS60828B1 - Cd40l-specifične konstrukcije izvedene iz tn3 i metode za njihovu primenu - Google Patents

Cd40l-specifične konstrukcije izvedene iz tn3 i metode za njihovu primenu

Info

Publication number: RS60828B1
Authority: RS; Serbia
Prior art keywords: cd40l; methods; specific; derived scaffolds; scaffolds
Prior art date: 2011-10-11

Application number

RS20201146A

Other languages

English (en)

Inventor

Anthony Coyle

Manuel Baca

Thomas Thisted

Stacey Drabic

Luba Grinberg

Shabazz Novarra

Vaheh Oganesyan

Ronald Herbst

David Kenneth Spencer

Original Assignee

Viela Bio Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-10-11

Filing date

2012-10-10

Publication date

2020-10-30

2012-10-10 Application filed by Viela Bio Inc filed Critical Viela Bio Inc

2020-10-30 Publication of RS60828B1 publication Critical patent/RS60828B1/sr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

RS20201146A 2011-10-11 2012-10-10 Cd40l-specifične konstrukcije izvedene iz tn3 i metode za njihovu primenu RS60828B1 (sr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161546028P	2011-10-11	2011-10-11
EP12840074.4A EP2771022B1 (en)	2011-10-11	2012-10-10	Cd40l-specific tn3-derived scaffolds and methods of use thereof
PCT/US2012/059477 WO2013055745A2 (en)	2011-10-11	2012-10-10	Cd40l-specific tn3-derived scaffolds and methods of use thereof

Publications (1)

Publication Number	Publication Date
RS60828B1 true RS60828B1 (sr)	2020-10-30

Family

ID=48082729

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RS20201146A RS60828B1 (sr)	2011-10-11	2012-10-10	Cd40l-specifične konstrukcije izvedene iz tn3 i metode za njihovu primenu

Country Status (22)

Country	Link
US (4)	US10000553B2 (sr)
EP (2)	EP2771022B1 (sr)
JP (4)	JP6140712B2 (sr)
KR (3)	KR102132997B1 (sr)
CN (3)	CN116063509A (sr)
AU (1)	AU2012323316B2 (sr)
BR (1)	BR112014008804A2 (sr)
CA (1)	CA2851667A1 (sr)
CY (1)	CY1123690T1 (sr)
DK (1)	DK2771022T3 (sr)
ES (1)	ES2819075T3 (sr)
HK (1)	HK1201463A1 (sr)
HR (1)	HRP20201513T1 (sr)
HU (1)	HUE051439T2 (sr)
LT (1)	LT2771022T (sr)
MX (2)	MX367013B (sr)
PT (1)	PT2771022T (sr)
RS (1)	RS60828B1 (sr)
RU (2)	RU2019133467A (sr)
SG (2)	SG11201400567QA (sr)
SI (1)	SI2771022T1 (sr)
WO (1)	WO2013055745A2 (sr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK3097926T3 (da) *	2007-11-01	2019-12-16	Univ Arkansas	Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner på Eimeria
RU2019133467A (ru) *	2011-10-11	2020-07-06	МЕДИММЬЮН, ЭлЭлСи	Cd40l-специфичные каркасные структуры, происходящие из tn3, и способы их применения
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
AU2015345202B2 (en)	2014-11-10	2021-05-13	Medimmune Limited	Binding molecules specific for CD73 and uses thereof
CN107428817B (zh)	2015-03-12	2022-07-12	免疫医疗有限责任公司	纯化白蛋白融合蛋白的方法
KR101810778B1 (ko) *	2015-06-23	2017-12-20	서울대학교산학협력단	Cd154 결합 폴리펩타이드 및 그 용도
ES2944982T3 (es)	2015-08-05	2023-06-27	Janssen Biotech Inc	Anticuerpos anti-CD154 y métodos para utilizarlos
BR112019014147A2 (pt) *	2017-01-09	2020-02-11	Biomunex Pharmaceuticals	Ligante polipeptídico para a preparação de anticorpos multiespecíficos
WO2019108541A1 (en) *	2017-11-28	2019-06-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Recombinant rsv g proteins and their use
US20210317220A1 (en) *	2018-09-24	2021-10-14	Janssen Biotech, Inc.	Method of providing safe administration of an anti-cd154 antibody
AU2019346457A1 (en) *	2018-09-26	2021-05-20	Viela Bio, Inc.	CD40l antagonist and uses thereof
WO2020086885A2 (en) *	2018-10-24	2020-04-30	Brandeis University	Multivalent glycopeptides that tightly bind to carbohydrate-binding monoclonal antibody family pgt128
CN113227135A (zh)	2018-12-28	2021-08-06	斯帕克斯治疗公司	用于治疗癌症和其他疾病的对紧密连接蛋白18.2具有特异性的结合分子、其组合物和方法
CN111440253B (zh) *	2019-01-17	2021-08-27	中国科学院上海药物研究所	立方形环糊精骨架-rgd组合物及其制备方法
AU2022276507A1 (en) *	2021-05-21	2023-12-07	Viela Bio, Inc.	Cd40l antagonist and uses thereof in the treatment of lupus nephritis

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4666884A (en)	1984-04-10	1987-05-19	New England Deaconess Hospital	Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
US5314995A (en)	1990-01-22	1994-05-24	Oncogen	Therapeutic interleukin-2-antibody based fusion proteins
CA2078689C (en)	1990-03-20	2003-02-11	Sherie L. Morrison	Chimeric antibodies with receptor binding ligands in place of their constant region
CA2079802C (en)	1990-04-05	2001-09-18	Roberto Crea	Walk-through mutagenesis
US7063943B1 (en)	1990-07-10	2006-06-20	Cambridge Antibody Technology	Methods for producing members of specific binding pairs
US5843701A (en)	1990-08-02	1998-12-01	Nexstar Pharmaceticals, Inc.	Systematic polypeptide evolution by reverse translation
US5866344A (en)	1991-11-15	1999-02-02	Board Of Regents, The University Of Texas System	Antibody selection methods using cell surface expressed libraries
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
ZA932522B (en)	1992-04-10	1993-12-20	Res Dev Foundation	Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5440018A (en)	1992-05-20	1995-08-08	The Green Cross Corporation	Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
CA2141602A1 (en)	1992-08-26	1994-03-03	Philip Leder	Use of the cytokine ip-10 as an anti-tumor agent
US5922545A (en)	1993-10-29	1999-07-13	Affymax Technologies N.V.	In vitro peptide and antibody display libraries
US5605793A (en)	1994-02-17	1997-02-25	Affymax Technologies N.V.	Methods for in vitro recombination
JPH10505750A (ja)	1994-09-16	1998-06-09	ザスクリップスリサーチインスティテュート	粘着および軸索の成長を刺激するサイトタクチン誘導体並びにその製造および使用方法
US5747035A (en)	1995-04-14	1998-05-05	Genentech, Inc.	Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US6096871A (en)	1995-04-14	2000-08-01	Genentech, Inc.	Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997043316A1 (en)	1996-05-10	1997-11-20	Beth Israel Deaconess Medical Center, Inc.	Physiologically active molecules with extended half-lives and methods of using same
US6699658B1 (en)	1996-05-31	2004-03-02	Board Of Trustees Of The University Of Illinois	Yeast cell surface display of proteins and uses thereof
US6673901B2 (en)	1997-06-12	2004-01-06	Research Corporation Technologies, Inc.	Artificial antibody polypeptides
JP2002505086A (ja)	1998-02-25	2002-02-19	レキシジェンファーマシューティカルズコーポレイション	抗体ベースの融合タンパク質の循環半減期の増強
AU731758B2 (en)	1998-07-08	2001-04-05	Mitsui Chemicals, Inc.	Method for secretory production of human growth hormone
EP1105427A2 (en)	1998-08-17	2001-06-13	Abgenix, Inc.	Generation of modified molecules with increased serum half-lives
WO2000032823A1 (en)	1998-12-02	2000-06-08	Phylos, Inc.	Dna-protein fusions and uses thereof
CA2351346C (en)	1998-12-10	2015-09-01	Phylos, Inc.	Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en)	1998-12-10	2006-10-03	Compound Therapeutics, Inc.	Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en)	1998-12-10	2004-11-16	Compound Therapeutics, Inc.	Protein scaffolds for antibody mimics and other binding proteins
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
ES2383332T3 (es)	1999-07-27	2012-06-20	Bristol-Myers Squibb Company	Procedimiento de ligación de aceptores de péptidos
US7022479B2 (en)	2000-01-24	2006-04-04	Compound Therapeutics, Inc.	Sensitive, multiplexed diagnostic assays for protein analysis
US8263741B2 (en)	2000-07-11	2012-09-11	Research Corporation Technologies, Inc.	Artificial antibody polypeptides
EP2141243A3 (en)	2000-10-16	2010-01-27	Brystol-Myers Squibb Company	Protein scaffolds for antibody mimics and other binding proteins
EP2341060B1 (en)	2000-12-12	2019-02-20	MedImmune, LLC	Molecules with extended half-lives, compositions and uses thereof
US6951725B2 (en)	2001-06-21	2005-10-04	Compound Therapeutics, Inc.	In vitro protein interaction detection systems
KR101271635B1 (ko) *	2001-12-21	2013-06-12	휴먼 게놈 사이언시즈, 인코포레이티드	알부민 융합 단백질
DK2339016T3 (da)	2002-03-29	2017-01-23	Danisco Us Inc	Øget produktion af subtilisiner
WO2003104418A2 (en)	2002-06-06	2003-12-18	Research Corporation Technologies, Inc.	Reconstituted polypeptides
CA2489348A1 (en)	2002-06-24	2003-12-31	Genentech, Inc.	Apo-2 ligand/trail variants and uses thereof
KR100524872B1 (ko)	2003-12-04	2005-11-01	씨제이 주식회사	인터페론 베타의 정제방법
KR20060129246A (ko)	2003-12-05	2006-12-15	컴파운드 쎄라퓨틱스, 인크.	타입 2 혈관 내피 성장 인자 수용체의 억제제
ES2372503T3 (es)	2004-07-06	2012-01-20	Bioren, Inc.	Mutagénesis revisada para desarrollar polipéptidos alterados con propiedades potenciadas.
KR100852415B1 (ko)	2004-07-13	2008-08-18	재단법인서울대학교산학협력재단	인간 테나신―ｃ 유래의 신규한 헤파린-결합부위를포함하는 폴리펩타이드 및 그의 유도체
GB0416651D0 (en)	2004-07-26	2004-08-25	Proteo Target Aps	Polypeptide
US8303955B2 (en) *	2005-05-26	2012-11-06	Seattle Genetics, Inc.	Humanized anti-CD40 antibodies and their methods of use
JP4959226B2 (ja)	2006-05-19	2012-06-20	独立行政法人産業技術総合研究所	スリーフィンガー様蛋白質ライブラリ
WO2008031098A1 (en)	2006-09-09	2008-03-13	The University Of Chicago	Binary amino acid libraries for fibronectin type iii polypeptide monobodies
AU2007325838B2 (en)	2006-11-22	2013-09-19	Bristol-Myers Squibb Company	Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
CN102014888A (zh)	2007-07-03	2011-04-13	达努塔·克鲁谢夫斯卡	α-酮戊二酸的新医药用途
US8470966B2 (en)	2007-08-10	2013-06-25	Protelica, Inc.	Universal fibronectin type III binding-domain libraries
JP5781762B2 (ja)	2007-08-10	2015-09-24	プロテリックス、インク	ユニバーサルｉｉｉ型フィブロネクチン結合ドメインのライブラリ
RU2010121967A (ru)	2007-10-31	2011-12-10	Медиммун, Ллк (Us)	Белковые каркасные структуры
CA2710835A1 (en) *	2007-12-27	2009-07-09	Novartis Ag	Improved fibronectin-based binding molecules and their use
EP2274331B1 (en)	2008-05-02	2013-11-06	Novartis AG	Improved fibronectin-based binding molecules and uses thereof
AR071874A1 (es)	2008-05-22	2010-07-21	Bristol Myers Squibb Co	Proteinas de dominio de armazon basadas en fibronectina multivalentes
KR20190025057A (ko)	2008-10-14	2019-03-08	제넨테크, 인크.	이뮤노글로불린 변이체 및 그의 용도
CA2741834C (en)	2008-10-31	2022-04-05	Centocor Ortho Biotech Inc.	Fibronectin type iii domain based scaffold compositions, methods and uses
TWI496582B (zh)	2008-11-24	2015-08-21	必治妥美雅史谷比公司	雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
EP2396011B1 (en)	2009-02-12	2016-04-13	Janssen Biotech, Inc.	Fibronectin type iii domain based scaffold compositions, methods and uses
WO2010128142A1 (en)	2009-05-07	2010-11-11	Novozymes Biopharma Dk A/S	Method for purifying albumin
US20120270797A1 (en)	2009-08-13	2012-10-25	Massachusetts Institute Of Technology	Engineered proteins including mutant fibronectin domains
CN105567699A (zh)	2009-10-30	2016-05-11	诺维信生物制药丹麦公司	白蛋白变体
WO2011051466A1 (en)	2009-11-02	2011-05-05	Novartis Ag	Anti-idiotypic fibronectin-based binding molecules and uses thereof
CN104610454A (zh)	2010-02-16	2015-05-13	米迪缪尼有限公司	Hsa相关组合物及使用方法
MX341119B (es) *	2010-04-13	2016-08-09	Medimmune Llc	Estructuras multiméricas específicas para ligando inductor de apoptosis relacionada con el factor de necrosis tumoral r2 (trail).
EP3757126A1 (en)	2010-11-05	2020-12-30	Novartis AG	Methods of treating psoriatic arthritis using il-17 antagonists
JP2014177354A (ja)	2011-07-05	2014-09-25	Asahi Glass Co Ltd	窓ガラス
RU2019133467A (ru)	2011-10-11	2020-07-06	МЕДИММЬЮН, ЭлЭлСи	Cd40l-специфичные каркасные структуры, происходящие из tn3, и способы их применения
MX2015005363A (es)	2012-11-08	2015-11-06	Novozymes Biopharma Dk As	Variantes de albumina.
CA2948944A1 (en)	2014-05-19	2015-11-26	Medimmune Limited	Treatment for rheumatoid arthritis
CN107428817B (zh)	2015-03-12	2022-07-12	免疫医疗有限责任公司	纯化白蛋白融合蛋白的方法
AU2019346457A1 (en)	2018-09-26	2021-05-20	Viela Bio, Inc.	CD40l antagonist and uses thereof

2012
- 2012-10-10 RU RU2019133467A patent/RU2019133467A/ru unknown
- 2012-10-10 RS RS20201146A patent/RS60828B1/sr unknown
- 2012-10-10 ES ES12840074T patent/ES2819075T3/es active Active
- 2012-10-10 KR KR1020147012468A patent/KR102132997B1/ko active IP Right Grant
- 2012-10-10 CA CA2851667A patent/CA2851667A1/en active Pending
- 2012-10-10 US US14/347,016 patent/US10000553B2/en active Active
- 2012-10-10 CN CN202211152182.5A patent/CN116063509A/zh active Pending
- 2012-10-10 SI SI201231843T patent/SI2771022T1/sl unknown
- 2012-10-10 LT LTEP12840074.4T patent/LT2771022T/lt unknown
- 2012-10-10 PT PT128400744T patent/PT2771022T/pt unknown
- 2012-10-10 EP EP12840074.4A patent/EP2771022B1/en active Active
- 2012-10-10 CN CN201280049742.2A patent/CN103874501B/zh active Active
- 2012-10-10 CN CN201810653215.1A patent/CN108948196B/zh active Active
- 2012-10-10 AU AU2012323316A patent/AU2012323316B2/en active Active
- 2012-10-10 HU HUE12840074A patent/HUE051439T2/hu unknown
- 2012-10-10 KR KR1020227028109A patent/KR20220116585A/ko not_active Application Discontinuation
- 2012-10-10 SG SG11201400567QA patent/SG11201400567QA/en unknown
- 2012-10-10 EP EP20177799.2A patent/EP3753567A1/en active Pending
- 2012-10-10 SG SG10201707813YA patent/SG10201707813YA/en unknown
- 2012-10-10 KR KR1020207019515A patent/KR102434073B1/ko active IP Right Grant
- 2012-10-10 BR BR112014008804A patent/BR112014008804A2/pt not_active Application Discontinuation
- 2012-10-10 MX MX2014004065A patent/MX367013B/es active IP Right Grant
- 2012-10-10 JP JP2014535807A patent/JP6140712B2/ja active Active
- 2012-10-10 DK DK12840074.4T patent/DK2771022T3/da active
- 2012-10-10 RU RU2014117511A patent/RU2704992C2/ru active
- 2012-10-10 WO PCT/US2012/059477 patent/WO2013055745A2/en active Application Filing
2014
- 2014-04-03 MX MX2019009104A patent/MX2019009104A/es unknown
2015
- 2015-03-02 HK HK15102049.0A patent/HK1201463A1/xx unknown
2017
- 2017-05-01 JP JP2017090963A patent/JP6539300B2/ja active Active
2018
- 2018-05-31 US US15/993,964 patent/US11104720B2/en active Active
2019
- 2019-06-07 JP JP2019106642A patent/JP7068231B2/ja active Active
2020
- 2020-09-22 HR HRP20201513TT patent/HRP20201513T1/hr unknown
- 2020-10-02 CY CY20201100927T patent/CY1123690T1/el unknown
2021
- 2021-07-28 US US17/387,269 patent/US11555062B2/en active Active
2022
- 2022-04-28 JP JP2022073975A patent/JP2022115916A/ja active Pending
- 2022-11-01 US US18/051,704 patent/US20230242619A1/en active Pending

Also Published As

Publication number	Publication date
KR20140077199A (ko)	2014-06-23
MX2014004065A (es)	2014-08-22
CN108948196B (zh)	2022-09-23
EP3753567A1 (en)	2020-12-23
JP2015501147A (ja)	2015-01-15
RU2019133467A (ru)	2020-07-06
US20230242619A1 (en)	2023-08-03
US10000553B2 (en)	2018-06-19
CY1123690T1 (el)	2022-03-24
US11104720B2 (en)	2021-08-31
SI2771022T1 (sl)	2020-12-31
JP6539300B2 (ja)	2019-07-03
JP2019205433A (ja)	2019-12-05
CN108948196A (zh)	2018-12-07
BR112014008804A2 (pt)	2017-06-13
CA2851667A1 (en)	2013-04-18
US20150098955A1 (en)	2015-04-09
CN103874501A (zh)	2014-06-18
LT2771022T (lt)	2020-12-10
HRP20201513T1 (hr)	2020-12-11
RU2014117511A (ru)	2015-11-20
KR102132997B1 (ko)	2020-07-14
PT2771022T (pt)	2020-09-14
WO2013055745A2 (en)	2013-04-18
US20220089688A1 (en)	2022-03-24
JP2017195884A (ja)	2017-11-02
HUE051439T2 (hu)	2021-03-01
SG11201400567QA (en)	2014-05-29
MX367013B (es)	2019-08-02
HK1201463A1 (en)	2015-09-04
CN103874501B (zh)	2018-07-20
AU2012323316A1 (en)	2014-03-20
MX2019009104A (es)	2019-09-10
AU2012323316B2 (en)	2017-08-10
KR102434073B1 (ko)	2022-08-18
EP2771022B1 (en)	2020-07-01
WO2013055745A3 (en)	2013-08-01
JP7068231B2 (ja)	2022-05-16
US11555062B2 (en)	2023-01-17
US20180312572A1 (en)	2018-11-01
DK2771022T3 (da)	2020-09-28
EP2771022A4 (en)	2015-08-05
KR20200085376A (ko)	2020-07-14
JP2022115916A (ja)	2022-08-09
JP6140712B2 (ja)	2017-05-31
KR20220116585A (ko)	2022-08-23
SG10201707813YA (en)	2017-11-29
ES2819075T3 (es)	2021-04-14
EP2771022A2 (en)	2014-09-03
CN116063509A (zh)	2023-05-05
RU2704992C2 (ru)	2019-11-01

Publication	Publication Date	Title
HRP20181628T1 (hr)	2018-12-14	Spojevi i postupci za njihovu upotrebu
HK1201463A1 (en)	2015-09-04	Cd40l-specific tn3-derived scaffolds and methods of use thereof cd40l- tn3-
HK1208439A1 (en)	2016-03-04	5-azaindazole compounds and methods of use 5-
EP2912178A4 (en)	2016-05-25	SUPER AMPLIFIER AND METHOD FOR USE THEREOF
IL227440B (en)	2019-01-31	Spherical support device and methods of use
EP2672820A4 (en)	2014-09-03	MANNOSID COMPOUNDS AND METHOD OF USE THEREOF
EP2675471A4 (en)	2015-01-28	HSA-RELATED COMPOSITIONS AND USE PROCESSES
ZA201401653B (en)	2019-09-25	Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
ZA201303793B (en)	2014-07-30	Substituted quinoline compounds and methods of use
EP2721063A4 (en)	2015-01-14	PCSK9 BINDING POLYPEPTIDES AND METHOD OF USE THEREOF
EP2670866A4 (en)	2015-09-02	BIOMARKERS AND METHODS OF USE
HK1254533A1 (zh)	2019-07-19	生化探針及其使用方法
EP2766078A4 (en)	2015-03-25	VENTILATION DEVICES AND USE METHOD THEREFOR
EP2852397A4 (en)	2016-03-23	HUWENTOXIN IV VARIANTS AND METHODS OF USE
EP2709999A4 (en)	2014-11-19	QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
EP2670245A4 (en)	2014-07-02	ALPHA-CÉTOHÉTÉROCYCLES AND METHODS OF MAKING AND USING THEM
IL215720A0 (en)	2011-12-29	Dehumidifier and method of use thereof
ZA201405829B (en)	2015-10-28	Cleaning arrangement and method of use
GB2493595B (en)	2014-09-10	Wheelchair and method of construction
GB201102364D0 (en)	2011-03-30	Lock means and method of use thereof
GB201122402D0 (en)	2012-02-08	Lock means and method of use thereof
GB201101586D0 (en)	2011-03-16	Lock means and method of use thereof
GB201014490D0 (en)	2010-10-13	Cleaning means and method of use thereof